This Is A Custom Widget

This Sliding Bar can be switched on or off in theme options, and can take any widget you throw at it or even fill it with your custom HTML Code. Its perfect for grabbing the attention of your viewers. Choose between 1, 2, 3 or 4 columns, set the background color, widget divider color, activate transparency, a top border or fully disable it on desktop and mobile.

This Is A Custom Widget

This Sliding Bar can be switched on or off in theme options, and can take any widget you throw at it or even fill it with your custom HTML Code. Its perfect for grabbing the attention of your viewers. Choose between 1, 2, 3 or 4 columns, set the background color, widget divider color, activate transparency, a top border or fully disable it on desktop and mobile.

Yearly Archives: 2018

/2018

Learning To Be Open

Dear reader, My name is Lianne Bankert. You may have heard of my brother Matthew and sister Kerrin, as well as my parents Ralph and Cathy. We live in Port Colborne, ON.  My brother and sister were diagnosed with MPS IIIA, and for that reason, my parents decided to adopt me from China when I [...]

Give the Gift of Hope! Donate today to the Annual Fundraiser

Help us help. Our support and education programs assist those affected in managing the diagnosis and progression of these rare, often devastating, disorders. Funds raised through donations and special events help fund research that provides hope for a brighter future for all children born with lysosomal diseases. Donate to the Annual Fund Click this link to [...]

RGX-121 for the Treatment of Mucopolysaccharidosis Type II (MPS II)

November 7, 2018 - REGENXBIO announced that the first subject was dosed at the Children's Hospital of Pittsburgh by a medical team led by Dr. Maria Escolar, Associate Professor of Pediatrics, Director of Program for the Study of Neurodevelopment in Rare Disorders at the Children's Hospital of Pittsburgh and primary investigator for the Phase I/II clinical [...]

Proud to Represent TeamMPS!!

On October 21st, I participated in the Scotiabank Marathon (and no, I didn’t run the Marathon… I did a measly 5km) alongside my fiancé and a few great friends.  This was my first time participating in a fundraiser for the Canadian MPS Society as an adult, and I can say that I have never been more [...]

Please give to the 2018 Annual Fund

Proceeds from the Annual Fund raise public awareness, support our families and strengthen the leadership and overall effectiveness of the Canadian MPS Society. Donate to the Annual Fund For more information, please call 1-800-667-1846 or email info@mpssociety.ca Thank you for helping to support Canadian families affected by MPS and related diseases and advance research to find a [...]

My Experience with MPS

When I was born, my mother noticed a small bump on my back. They said I was fine and so, my mother had another child, my brother. Nevertheless, my mother felt something might be wrong… I was easily tired of walking and standing up. The bump didn’t go away. When I was four, my brother and [...]

View Jessica Gentle’s Presentation

In May of 2017, Jessica Gentle spoke at our annual Ignite Hope Fundraising Gala and wowed everyone with her delightful presentation! PowerPoint - Jessica

Introducing Venture through Life

 Hello everyone! We are very pleased to welcome you our special blog Venture through Life. This project, very dear to our hearts, has been a long time in the making and we’re eager to get this journey started. We are both members of the Canadian MPS Society and have been for many years. We will be writing [...]

Sangamo Announces 16 Week Clinical Results Including Reductions In Glycosaminoglycans In Phase 1/2 Trial Evaluating SB-913, A Zinc Finger Nuclease Genome Editing Treatment For MPS II (Hunter Syndrome)

RICHMOND, Calif., Sept. 5, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO) today reported 16 week reductions in urinary glycosaminoglycans (GAGs), a key biomarker of Mucopolysaccharidosis Type II (MPS II) disease pathophysiology, in Cohort 2 of the Phase 1/2 CHAMPIONS Study evaluating SB-913.  SB-913 is a zinc finger nuclease (ZFN) in vivo genome editing product candidate being [...]